1 |
Chatterjee S, Khunti K, Davies MJ. Type 2 diabetes[J]. Lancet, 2017, 389(10085): 2239. |
2 |
Laakso M. Biomarkers for type 2 diabetes[J]. Mol Metab, 2019, 27: S139. |
3 |
Jia WP, Weng JP, Zhu DL, et al. Standards of medical care for type 2 diabetes in China 2019[J]. Diabetes Metab Res Rev, 2019, 35(6): e3158. |
4 |
Hu C, Jia WP. Diabetes in China: epidemiology and genetic risk factors and their clinical utility in personalized medication[J]. Diabetes, 2018, 67(1): 3. |
5 |
Ma RC, Lin X, Jia W. Causes of type 2 diabetes in China[J]. Lancet Diabetes Endocrinol, 2014, 2(12): 980. |
6 |
Bellou V, Belbasis L, Tzoulaki I, et al. Risk factors for type 2 diabetes mellitus: an exposure-wide umbrella review of meta-analyses[J]. PLoS One, 2018, 13(3): e0194127. |
7 |
Radu AF, Bungau SG. Management of rheumatoid arthritis: an overview[J]. Cells, 2021, 10(11): 2857. |
8 |
Su CC, Chen IeC, Young FN, et al. Risk of diabetes in patients with rheumatoid arthritis: a 12-year retrospective cohort study[J]. J Rheumatol, 2013, 40(9): 1513. |
9 |
Solomon DH, Love TJ, Canning C, et al. Risk of diabetes among patients with rheumatoid arthritis, psoriatic arthritis and psoriasis[J]. Ann Rheum Dis, 2010, 69(12): 2114. |
10 |
Han CL, Robinson DW Jr, Hackett MV, et al. Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis[J]. J Rheumatol, 2006, 33(11): 2167. |
11 |
Simard JF, Mittleman MA. Prevalent rheumatoid arthritis and diabetes among NHANES III participants aged 60 and older[J]. J Rheumatol, 2007, 34(3): 469. |
12 |
Evans DM, Davey Smith G. Mendelian randomization: new applications in the coming age of hypothesis-free causality[J]. Annu Rev Genomics Hum Genet, 2015, 16: 327. |
13 |
Bae SC, Lee YH. Coffee consumption and the risk of rheumatoid arthritis and systemic lupus erythematosus: a Mendelian randomization study[J]. Clin Rheumatol, 2018, 37(10): 2875. |
14 |
Eyre S, Bowes J, Diogo D, et al. High-density genetic mapping identifies new susceptibility loci for rheumatoid arthritis[J]. Nat Genet, 2012, 44(12): 1336. |
15 |
Xue AL, Wu Y, Zhu ZH, et al. Genome-wide association analyses identify 143 risk variants and putative regulatory mechanisms for type 2 diabetes[J]. Nat Commun, 2018, 9(1): 2941. |
16 |
Burgess S, Butterworth A, Thompson SG. Mendelian randomization analysis with multiple genetic variants using summarized data[J]. Genet Epidemiol, 2013, 37(7): 658. |
17 |
Bae SC, Lee YH. Vitamin D level and risk of systemic lupus erythematosus and rheumatoid arthritis: a Mendelian randomization[J]. Clin Rheumatol, 2018, 37(9): 2415. |
18 |
Bowden J, Davey Smith G, Haycock PC, et al. Consistent estimation in mendelian randomization with some invalid instruments using a weighted median estimator[J]. Genet Epidemiol, 2016, 40(4): 304. |
19 |
Burgess S, Thompson SG. Interpreting findings from Mendelian randomization using the MR-Egger method[J]. Eur J Epidemiol, 2017, 32(5): 377. |
20 |
Giles JT, Danielides S, Szklo M, et al. Insulin resistance in rheumatoid arthritis: disease-related indicators and associations with the presence and progression of subclinical atherosclerosis[J]. Arthritis Rheumatol, 2015, 67(3): 626. |
21 |
Ruscitti P, Ursini F, Cipriani P, et al. Prevalence of type 2 diabetes and impaired fasting glucose in patients affected by rheumatoid arthritis: results from a cross-sectional study[J]. Medicine (Baltimore), 2017, 96(34): e7896. |
22 |
Jiang P, Li H, Li X. Diabetes mellitus risk factors in rheumatoid arthritis: a systematic review and meta-analysis[J]. Clin Exp Rheumatol, 2015, 33(1): 115. |
23 |
Liu XZ, Gao Y, Fan J, et al. Metabolic abnormalities in rheumatoid arthritis patients with comorbid diabetes mellitus[J]. Clin Rheumatol, 2018, 37(1): 219. |
24 |
Nicolau J, Lequerré T, Bacquet H, et al. Rheumatoid arthritis, insulin resistance, and diabetes[J]. Joint Bone Spine, 2017, 84(4): 411. |
25 |
Lu MC, Yan ST, Yin WY, et al. Risk of rheumatoid arthritis in patients with type 2 diabetes: a nationwide population-based case-control study[J]. PLoS One, 2014, 9(7): e101528. |
26 |
Donath MY. Targeting inflammation in the treatment of type 2 diabetes: time to start[J]. Nat Rev Drug Discov, 2014, 13(6): 465. |
27 |
Moore MN, Wallace BI. Glucocorticoid and opioid use in rheumatoid arthritis management[J]. Curr Opin Rheumatol, 2021, 33(3): 277. |
28 |
Roubille C, Richer V, Starnino T, et al. The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis[J]. Ann Rheum Dis, 2015, 74(3): 480. |
29 |
Baghdadi LR. Effect of methotrexate use on the development of type 2 diabetes in rheumatoid arthritis patients: a systematic review and meta-analysis[J]. PLoS One, 2020, 15(7): e0235637. |
30 |
Toledo FGS, Miller RG, Helbling NL, et al. The effects of hydroxychloroquine on insulin sensitivity, insulin clearance and inflammation in insulin-resistant adults: a randomized trial[J]. Diabetes Obes Metab, 2021, 23(6): 1252. |
31 |
Jin YZ, Chen SK, Liu J, et al. Risk of incident type 2 diabetes mellitus among patients with rheumatoid arthritis: a population-based cohort study[J]. Arthritis Care Res (Hoboken), 2020, 72(9): 1248. |
32 |
Verma AK, Bhatt D, Goyal Y, et al. Association of rheumatoid arthritis with diabetic comorbidity: correlating accelerated insulin resistance to inflammatory responses in patients[J]. J Multidiscip Healthc, 2021, 14: 809. |
33 |
Riaz H, Khan MS, Siddiqi TJ, et al. Association between obesity and cardiovascular outcomes: a systematic review and meta-analysis of mendelian randomization studies[J]. JAMA Netw Open, 2018, 1(7): e183788. |